A BILL 
To direct the Secretary of Health and Human Services to 
support research on, and expanded access to, investiga-
tional drugs for amyotrophic lateral sclerosis, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
21:54 Nov 13, 2020
H8662
jbell on DSKJLSW7X2PROD with BILLS
2 
•HR 8662 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Accelerating Access 
2
to Critical Therapies for ALS Act’’. 
3
SEC. 2. GRANTS FOR RESEARCH ON AND EXPANDED AC-
4
CESS TO EXPERIMENTAL THERAPIES FOR 
5
ALS. 
6
(a) IN GENERAL.—The Secretary of Health and 
7
Human Services shall award grants to eligible entities for 
8
purposes of supporting research on, and expanded access 
9
for individuals to, investigational drugs for the prevention, 
10
diagnosis, mitigation, treatment, or cure of amyotrophic 
11
lateral sclerosis pursuant to an expanded access request 
12
submitted, and allowed to proceed by the Secretary, under 
13
section 561 of the Federal Food, Drug, and Cosmetic Act 
14
(21 U.S.C. 360bbb). 
15
(b) APPLICATION.—An eligible entity seeking a grant 
16
under this section shall submit to the Secretary an appli-
17
cation at such time, in such manner, and containing such 
18
information as the Secretary shall specify. Such applica-
19
tion shall specify a research objective relating to expand-
20
ing access to investigational drugs (as described in sub-
21
section (a)) that would be supported by the award of such 
22
grant. 
23
(c) SELECTION.—Not later than 90 days after the 
24
date of submission of an application for a grant under this 
25
section, the Secretary shall determine whether to award 
26
21:54 Nov 13, 2020
H8662
jbell on DSKJLSW7X2PROD with BILLS
3 
•HR 8662 IH
the grant, taking into consideration whether awarding 
1
such grant will support a research objective relating to ex-
2
panding access to investigational drugs (as described in 
3
subsection (a)), consistent with the mission of the Na-
4
tional Institutes of Health. 
5
(d) USE OF FUNDS.—An eligible entity may use 
6
funds received through the grant— 
7
(1) to pay the manufacturer or sponsor for the 
8
direct costs of such drug (as authorized under sec-
9
tion 312.8(d) of title 21, Code of Federal Regula-
10
tions (or successor regulations)), if such costs are 
11
justified as part of peer review of the grant; 
12
(2) for the entity’s direct costs incurred in pro-
13
viding such drug consistent with the research mis-
14
sion of the grant; or 
15
(3) for the direct and indirect costs of the enti-
16
ty in conducting research with respect to the drug 
17
involved. 
18
(e) DEFINITIONS.—In this section: 
19
(1) The term ‘‘eligible entity’’ means a partici-
20
pating clinical trial site or sites sponsored by a small 
21
business concern (as defined in section 3(a) of the 
22
Small Business Act (15 U.S.C. 632(a)) that is the 
23
sponsor of a drug that is the subject of an investiga-
24
tional new drug application under section 505(i) of 
25
21:54 Nov 13, 2020
H8662
jbell on DSKJLSW7X2PROD with BILLS
4 
•HR 8662 IH
the Federal Food, Drug, and Cosmetic Act (21 
1
U.S.C. 355(i)). 
2
(2) The term ‘‘participating clinical trial’’ 
3
means a phase 3 clinical trial conducted pursuant to 
4
an exemption under section 505(i) of the Federal 
5
Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) or 
6
section 351(a) of the Public Health Service Act (42 
7
U.S.C. 262(a)) to investigate a drug intended to pre-
8
vent, diagnose, mitigate, treat, or cure amyotrophic 
9
lateral sclerosis. 
10
(3) The term ‘‘participating clinical trial site’’ 
11
means a nonprofit or public health care facility, or 
12
network of facilities, at which patients participating 
13
in a participating clinical trial receive an investiga-
14
tional drug through such trial. 
15
SEC. 3. HHS COLLABORATIVE FOR NEURODEGENERATIVE 
16
DISEASES. 
17
(a) ESTABLISHMENT.—Not later than one year after 
18
the date of the enactment of this Act, the Secretary of 
19
Health and Human Services shall establish and implement 
20
a Collaborative for Neurodegenerative Diseases between 
21
the National Institutes of Health and the Food and Drug 
22
Administration (to be known and referred to in this sec-
23
tion as the ‘‘Collaborative’’), which shall— 
24
21:54 Nov 13, 2020
H8662
jbell on DSKJLSW7X2PROD with BILLS
5 
•HR 8662 IH
(1) enter into a cooperative agreement, con-
1
tract, or other instrument with a private entity or 
2
entities under which such private entity or entities 
3
will operate the Collaborative; 
4
(2) focus on advancing regulatory improvements 
5
and scientific research that will support and accel-
6
erate the development and approval of drugs for pa-
7
tients with amyotrophic lateral sclerosis; 
8
(3) foster the development of effective drugs 
9
that improve the lives of people that suffer from rare 
10
neurodegenerative diseases; and 
11
(4) share information with the Secretary to ad-
12
vance the purposes specified in paragraph (3), such 
13
as through carrying out the grant programs under 
14
sections 2 and 5 and developing the action plan 
15
under section 4. 
16
(b) GIFTS.— 
17
(1) IN GENERAL.—The Collaborative may so-
18
licit and accept gifts, grants, and other donations, 
19
establish accounts, and invest and expend funds in 
20
support of pre-competitive research and research as-
21
sociated with phase 3 and phase 4 clinical trials con-
22
ducted with respect to investigational drugs that are 
23
the subjects of expanded access applications under 
24
21:54 Nov 13, 2020
H8662
jbell on DSKJLSW7X2PROD with BILLS
6 
•HR 8662 IH
section 561 of the Federal Food, Drug, and Cos-
1
metic Act (21 U.S.C. 360bbb). 
2
(2) USE.—In addition to any amounts appro-
3
priated for purposes of carrying out this section, the 
4
Collaborative may use, without further appropria-
5
tion, any funds derived from a gift, grant, or other 
6
donation accepted pursuant to paragraph (1). 
7
(c) ADVISORY PANEL.— 
8
(1) IN GENERAL.—The Collaborative shall con-
9
vene an advisory panel to conduct a review of the de-
10
sign and implementation of the programs authorized 
11
by this Act. Such panel shall include representatives 
12
of patients, treating physicians, national organiza-
13
tions that facilitate provision of care services, re-
14
searchers, drug sponsors, drug manufacturers, and 
15
Federal agencies. 
16
(2) REPORT.—The advisory panel convened 
17
under paragraph (1) shall, not later than 18 months 
18
after the date of the enactment of this Act, submit 
19
to the Committee on Energy and Commerce of the 
20
House of Representatives and the Committee on 
21
Health, Education, Labor, and Pensions of the Sen-
22
ate a report that contains— 
23
(A) the findings and conclusions of the re-
24
view conducted under paragraph (1); and 
25
21:54 Nov 13, 2020
H8662
jbell on DSKJLSW7X2PROD with BILLS
7 
•HR 8662 IH
(B) recommendations for carrying out the 
1
programs under this Act during the 2-year pe-
2
riod following the submission of such report, in-
3
cluding recommendations relating to the inclu-
4
sion of additional neurodegenerative diseases or 
5
disease areas within the grant programs under 
6
sections 2 and 5. 
7
(d) DUTIES AND AUTHORITIES.—The Collaborative 
8
shall identify and implement strategies for the Secretary— 
9
(1) for purposes of expediting the approval of 
10
drugs to treat amyotrophic lateral sclerosis, includ-
11
ing through coordination among the centers of the 
12
Food and Drug Administration to achieve the goals 
13
specified in the draft guidance for drug sponsors en-
14
titled ‘‘Amyotrophic Lateral Sclerosis: Developing 
15
Drugs for Treatment Guidance for Industry’’ pub-
16
lished in September 2019; 
17
(2) to facilitate access to investigational drugs 
18
for amyotrophic lateral sclerosis pursuant to an ex-
19
panded access request under section 561 of the Fed-
20
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
21
360bbb) in a similar manner as investigational drugs 
22
for cancer are provided through Project Facilitate of 
23
the Center of Excellence for Oncology; 
24
21:54 Nov 13, 2020
H8662
jbell on DSKJLSW7X2PROD with BILLS
8 
•HR 8662 IH
(3) with respect to the rare neurodegenerative 
1
disease grant program established under section 5; 
2
(4) to define or develop the regulatory and 
3
translational pathway for emerging therapeutic cat-
4
egories; 
5
(5) to share, within the Collaborative, findings 
6
and insights related to pre-competitive research and 
7
research associated with phase 3 and phase 4 clin-
8
ical trials conducted with respect to investigational 
9
drugs that are the subjects of expanded access appli-
10
cations under section 561 of the Federal Food, 
11
Drug, and Cosmetic Act (21 U.S.C. 360bbb); and 
12
(6) to develop and implement an ongoing mech-
13
anism to share feedback and information and de-
14
velop strategies with the neurodegenerative disease 
15
community, including patients, treating physicians, 
16
national organizations that facilitate provision of 
17
care services, access, and research, researchers, drug 
18
sponsors, drug manufacturers, and Federal agencies. 
19
SEC. 4. NEURODEGENERATIVE DISEASE ACTION PLAN. 
20
(a) IN GENERAL.—Not later than 6 months after the 
21
date of the enactment of this Act, the Secretary of Health 
22
and Human Services shall publish an action plan describ-
23
ing actions the Department of Health and Human Serv-
24
ices, through the National Institutes of Health and Food 
25
21:54 Nov 13, 2020
H8662
jbell on DSKJLSW7X2PROD with BILLS
9 
•HR 8662 IH
and Drug Administration, intend to take during the 5-year 
1
period following publication of the plan with respect to 
2
program enhancements, policy development, regulatory 
3
science initiatives, and other appropriate initiatives to— 
4
(1) foster the development of safe and effective 
5
drugs that improve the lives of people living with 
6
rare neurodegenerative diseases as quickly as pos-
7
sible; and 
8
(2) facilitate access to investigational drugs. 
9
(b) CONTENTS.—The action plan published under 
10
subsection (a) shall— 
11
(1) identify appropriate representation from 
12
within the Food and Drug Administration and Na-
13
tional Institutes of Health to be responsible for im-
14
plementation of such action plan; and 
15
(2) include elements to facilitate— 
16
(A) interactions and collaboration between 
17
the Food and Drug Administration, including 
18
the review centers thereof, and stakeholders in-
19
cluding patients, sponsors, and external bio-
20
medical community; 
21
(B) consideration of cross-cutting clinical 
22
and regulatory policy issues, including consist-
23
ency of regulatory advice and decisionmaking; 
24
21:54 Nov 13, 2020
H8662
jbell on DSKJLSW7X2PROD with BILLS
10 
•HR 8662 IH
(C) identification of key regulatory science 
1
and policy issues critical to advancing develop-
2
ment of safe and effective drugs; and 
3
(D) engagement by staff of the relevant 
4
centers of the Food and Drug Administration 
5
and other relevant offices of the Food and Drug 
6
Administration and National Institutes of 
7
Health with the designated leadership of the 
8
Collaborative. 
9
SEC. 5. RARE NEURODEGENERATIVE DISEASE GRANT PRO-
10
GRAM. 
11
The Secretary of Health and Human Services, acting 
12
through the Commissioner of Food and Drugs, shall carry 
13
out a program of awarding grants to, and contracts en-
14
tered into with, public and private entities to cover the 
15
costs of research on and development of interventions in-
16
tended to prevent, diagnose, mitigate, treat, or cure 
17
amyotrophic lateral sclerosis and other life-threatening or 
18
severely debilitating neurodegenerative diseases, including 
19
costs incurred with respect to the development and critical 
20
evaluation of tools, methods, and processes— 
21
(1) to characterize such neurodegenerative dis-
22
eases and their natural history; 
23
(2) to identify molecular targets for such 
24
neurodegenerative diseases; and 
25
21:54 Nov 13, 2020
H8662
jbell on DSKJLSW7X2PROD with BILLS
11 
•HR 8662 IH
(3) to increase efficiency and productivity of 
1
clinical development of therapies, including advanc-
2
ing rational therapeutic development and working to 
3
establish clinical trial networks. 
4
SEC. 6. AUTHORIZATION OF APPROPRIATIONS. 
5
For purposes of carrying out this Act, there are au-
6
thorized to be appropriated $100,000,000 for each of fis-
7
cal years 2022 through 2026. 
8
Æ 
21:54 Nov 13, 2020
H8662
jbell on DSKJLSW7X2PROD with BILLS
